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Abstract
Background: Many patients with acute coronary syndrome in the United States electively choose to undergo
percutaneous coronary angioplasty. One of the many risks associated with this procedure is peri-procedural
myocardial infarction (MI). Recently, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors otherwise
known as statins administered before the procedure have been shown to reduce the incidence of peri-
procedural myocardial infarction. Many of the studies that have been done have used atorvastatin and have
been limited to peri-procedural outcomes. Will administering a loading dose of rosuvastatin before
percutaneous coronary intervention (PCI) improve mid and long term outcomes?
Methods: An exhaustive search of available medical literature was conducted using Medline-OVID, EBSCO,
CINAHL, Health Source-Consumer, and Web of Science using the keywords: rosuvastatin and percutaneous
coronary intervention. Relevant articles were assessed for quality using GRADE.
Results: Three studies, with one including a 12-month follow up study met inclusion criteria. A prospective
randomized trial of 445 patients that included a 12-month follow up study concluded that a 40mg loading
dose of rosuvastatin before PCI improved 12-month clinical outcomes. A single center, prospective,
randomized trial of 160 patients demonstrated that a 40mg loading dose of rosuvastatin before elective PCI
decreased the incidence of postprocedural MI during a period of 12 months compared to standard treatment.
A randomized, prospective, double-blind, placebo-controlled trial of 125 patients concluded that a 20mg
loading dose of rosuvastatin before PCI reduces the incidence of postprocedural MI in patients with acute
coronary syndrome.
Conclusion: A loading dose of rosuvastatin has been shown to reduce the incidence of both myocardial
infarction and major adverse cardiac events up to 12 months post-procedure. More research is needed to
discover the exact mechanism of action. Furthermore, more research is needed to address the correct dosing,
timing of administration, and whether or not rosuvastatin is better than other statins in the setting of PCI.
Lastly, can patients with ST-elevation myocardial infarctions undergoing PCI benefit from the same
treatment?
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Abstract   
 
Background: Many patients with acute coronary syndrome in the United States 
electively choose to undergo percutaneous coronary angioplasty. One of the many risks 
associated with this procedure is peri-procedural myocardial infarction (MI). Recently, 3-
hydroxy-3-methylglutaryl coenzyme A reductase inhibitors otherwise known as statins 
administered before the procedure have been shown to reduce the incidence of peri-
procedural myocardial infarction. Many of the studies that have been done have used 
atorvastatin and have been limited to peri-procedural outcomes. Will administering a 
loading dose of rosuvastatin before percutaneous coronary intervention (PCI) improve 
mid and long term outcomes?  
 
Methods:  An exhaustive search of available medical literature was conducted using 
Medline-OVID, EBSCO, CINAHL, Health Source-Consumer, and Web of Science using 
the keywords: rosuvastatin and percutaneous coronary intervention. Relevant articles 
were assessed for quality using GRADE.   
 
Results:  Three studies, with one including a 12-month follow up study met inclusion 
criteria. A prospective randomized trial of 445 patients that included a 12-month follow 
up study concluded that a 40mg loading dose of rosuvastatin before PCI improved 12-
month clinical outcomes. A single center, prospective, randomized trial of 160 patients 
demonstrated that a 40mg loading dose of rosuvastatin before elective PCI decreased the 
incidence of postprocedural MI during a period of 12 months compared to standard 
treatment. A randomized, prospective, double-blind, placebo-controlled trial of 125 
patients concluded that a 20mg loading dose of rosuvastatin before PCI reduces the 
incidence of postprocedural MI in patients with acute coronary syndrome. 
 
Conclusion:  A loading dose of rosuvastatin has been shown to reduce the incidence of 
both myocardial infarction and major adverse cardiac events up to 12 months post-
procedure. More research is needed to discover the exact mechanism of action. 
Furthermore, more research is needed to address the correct dosing, timing of 
administration, and whether or not rosuvastatin is better than other statins in the setting of 
PCI. Lastly, can patients with ST-elevation myocardial infarctions undergoing PCI 
benefit from the same treatment?  
 
Keywords:  Rosuvastatin and percutaneous coronary intervention 
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Loading Dose of Rosuvastatin Before PCI and its Beneficial Post-
Procedural Effects: A Systematic Review 
 
BACKGROUND 
 Approximately 1.4 million patients undergo percutaneous coronary intervention 
(PCI) in the United States every year.1 Many of these patients are at risk of peri-
procedural myocardial infarction (MI).2 Ensuing major post-procedural adverse cardiac 
events such as death and MI are related to the amount of cardiac enzymes that are 
released during the injury.3,4  
Three-hydroxy-three-methylglutaryl coenzyme A reductase inhibitors, otherwise 
known as statins, have been used for many years in the medical field to reduce the 
amount of LDL cholesterol in humans. Many studies5,6  have demonstrated the beneficial 
effects statins have on morbidity and mortality. Recently these beneficial effects have 
been thought to stem from not only the cholesterol lowering action but also the so called 
pleiotropic effects of statins. These pleiotropic properties include beneficial effects on 
endothelial function, enhancing the stability of atherosclerotic plaques, inhibiting 
vascular smooth muscle proliferation, and reducing vascular inflammation.7 This can be 
seen in the new guidelines put out this November by the American Heart Association and 
the American College of Cardiology. In the new guidelines,8,9 cholesterol levels do not 
matter anymore, it is all about risk.8,9 Due possibly to their pleiotropic effects, statins are 
now the drug class being looked at for controlling these risks.  
In recent years, studies have confirmed that statin administration before PCI 
reduces peri-procedural MI’s in patients with stable angina.5,6,10 Most of these landmark 
studies used atorvastatin and were limited to peri-procedural outcomes.5,6,10 Does 
 - 8 -  
administering a loading dose of rosuvastatin before undergoing percutaneous coronary 
intervention improve postprocedural outcomes in patients with acute coronary syndrome 




An exhaustive search of available medical literature was conducted using 
Medline-OVID, EBSCO, CINAHL, Health Source-Consumer, and Web of Science using 
the keywords: rosuvastatin and percutaneous coronary intervention. Eligibility criteria 
was met by the study being done on humans, published in English, and by containing 
data on post-procedural outcomes defined by a minimum of at least 24 hours post 
percutaneous coronary intervention (PCI). Included studies were assessed for quality 
using the Grading of Recommendations, Assessment, Development, and Evaluation 
(GRADE).11 
RESULTS 
 The initial result of the search yielded 85 articles for review. After screening 
relevant articles for the inclusion criteria, a total of 4 articles remained. These articles 
consisted of three randomized controlled trials12-14 and a 12-month15 follow up to one of 
the trials. See Table I. 
Yun et al 
 This prospective randomized study12 that included a 12-month follow up study15 
investigated the effect of administering a high loading dose of rosuvastatin on patients 
with non-ST-segment elevation acute coronary syndrome (ACS) before PCI. The trial 
enrolled 445 adult patients with non-ST-segment elevation ACS that received diagnostic 
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coronary angiography. The primary endpoint was the occurrence of peri-procedural 
myocardial infarction (MI). The secondary endpoints included 1) any post-procedural 
increase in markers of myocardial injury above upper limit of normal or greater or equal 
to 20% increase of the baseline value, 2) peak values of high-sensitivity c-reactive protein 
(hsCRP) after PCI, and 3) occurrence of major adverse cardiac events (MACE) during 
the first 30 days up to 12 months. MACE was defined as death, Q wave MI, target vessel 
revascularization, and ischemic stroke.12,15 
 Eligibility criteria consisted of patients with non-ST-segment elevation ACS that 
received diagnostic coronary angiography. Exclusion criteria consisted of prior use of 
statins, cardiogenic shock, those in which medical treatment was recommended, those in 
which coronary artery bypass graft (CABG) was recommended, and those with severe 
hepatic or renal diseases. The 445 patients who met the criteria were then randomized by 
a 1:1 ratio into two groups. There were 220 patients in the control group and 225 patients 
in the rosuvastatin group. One group did not receive rosuvastatin (control group) and the 
other group received 40mg of rosuvastatin (rosuvastatin group) before PCI. Both groups 
did receive 300mg of aspirin and 300mg of clopidogrel before the procedure.12,15 Post-
procedurally both groups also received 200mg of aspirin, 75mg of clopidogrel, and 10mg 
of rosuvastatin daily. Statistical difference was not found between the two groups’ 
baseline characteristics. 12,15 
 Rosuvastatin administration prior to PCI was found to significantly reduce the 
incidence of myocardial infarction, 30 day MACE, and MACE at 12 months. Myocardial 
infarction was detected after PCI in 5.8% of those in the rosuvastatin group and 11.4% of 
the patients in the control group (P=0.035). Moreover, patients who received rosuvastatin 
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loading prior to PCI had a lower incidence of 30 day MACE compared to the control 
group (6.7% vs. 15.9%, P=0.002, respectively).12,15 Furthermore, rosuvastatin loading 
before PCI was also shown to reduce MACE at 12 months. Multivariate analysis revealed 
that rosuvastatin loading (OR = 0.5; 95%CI =0.3-0.8, P=0.006) was the independent 
predictor for decreased risk of 12-month MACE.12,15 
 The authors did find some limitations of this study. They cited the fact that their 
study was not blinded, and their sample size was small. The authors did express the need 
for more research to confirm their results. The authors did conclude that their study does 
support the use of high dose rosuvastatin loading therapy before PCI in patients with 
ACS.12,15 
The ROMA Trial 
 This single center, prospective, randomized trial13 set out to assess whether a 
single, high loading dose of rosuvastatin is effective in reducing the post-procedural 
elevation of cardiac biomarkers after elective, non-urgent coronary angioplasty. The 
study enrolled 160 adult patients. The primary endpoint of the study was the incidence of 
peri-procedural MI. This was defined as CK-MB elevation above 3 times upper limit of 
normal or any CK-MB elevation associated with chest pain, ST-segment, or T-wave 
abnormalities in patients undergoing non-urgent PCI. The secondary endpoint was the 
incidence of major adverse cardiac and cerebrovascular events (MACCE). They defined 
MACCE as cardiac death, peri-procedural MI, spontaneous MI, target vessel 
revascularization, and stroke.13 
 The inclusion criteria for this study was age greater than 18, elective PCI due to 
symptomatic coronary artery disease, and “de novo” lesions in a native coronary artery, 
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baseline cardiac enzymes had to be within normal limits, and no previous statin therapy. 
Exclusion criteria consisted of ACS with elevated cardiac enzymes, primary or rescue 
PCI, renal failure, previous MI, left ventricular ejection fraction of less than 30%, 
elevated liver enzymes, and inability to give consent.13 
 The day before the procedure the 160 eligible patients were randomly assigned 
into two groups. The randomization was done by a 1:1 ratio using computer-generated 
random numbers. Statistical prognostic difference was not found between the two groups. 
One group would receive 40mg of rosuvastatin within 24 hours of PCI (rosuvastatin 
group) and the other group would not receive the rosuvastatin (control group). Both 
groups would receive 300mg of clopidogrel, and 500mg of aspirin 24 hours before the 
procedure. Post-procedurally both groups were put on a regime of aspirin, clopidogrel, 
and 20mg of rosuvastatin.13 
 Rosuvastatin administration prior to PCI was found to significantly reduce the 
incidence of peri-procedural MI as well as overall MACCE. Peri-procedural MI was the 
main difference between the two groups (8.7% vs. 26.4%; P = 0.003, respectively). The 
study also showed that at 30 days and 12 months the rate of overall MACCE was 
substantially lower in the rosuvastatin group compared to the control group (8.7% vs. 
30%; P = 0.001 and 12.5% vs. 35%; P = 0.001 respectively). Moreover, multivariate 
analysis showed that pretreatment with rosuvastatin significantly reduced the risk of 
overall MACCE (hazard ratio 0.124, 95% CI 0.041 to 0.292; P = 0.022).13 
 The limitation of the study pointed out by the authors was mainly the fact that 
their study was not blinded.13 The authors did state that their study does support the 
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cardioprotective effect of a single high (40mg) loading dose of rosuvastatin administered 
within 24 hours before stent implantation.13 
Wang et al 
 This randomized, prospective, double-blind, placebo-controlled trial14 was set up 
to investigate whether pre-treatment with rosuvastatin can reduce procedural myocardial 
damage in patients with ACS undergoing elective PCI. The study enrolled 125 adult 
patients. Exclusion criteria was a previous history of statin treatment, current cardiogenic 
shock, patients in whom medical management was recommended, those in whom 
coronary artery bypass graft was recommended, and patients that had severe hepatic or 
renal disease.14 
 The primary endpoints included major adverse cardiac events (MACE) that 
occurred within 30 days after PCI. These included cardiac death, MI, and target artery 
revascularization. The secondary endpoint was an elevation in cardiac markers above the 
upper normal limit within 30 days post PCI.14 
 The 125 eligible patients were randomly assigned to either receive a 20mg 
loading dose of rosuvastatin 2 to 4 hours before PCI (rosuvastatin group) or to receive the 
placebo treatment (control group). Randomization was performed in a 1:1 ratio. 
Furthermore, physicians performing the procedure were blinded to the randomization 
assignment.14 Statistical prognostic difference was not found between the two groups. 
Both groups, however, did receive 100mg of aspirin and 75mg of clopidogrel daily, with 
a total dose of at least 300mg before PCI. After the procedure both groups were treated 
with low-molecular weight heparin for 3 to 5 days, 75mg of clopidogrel a day for at least 
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12 months, 10mg of rosuvastatin every night for at least one month, and 100mg of aspirin 
a day for as long as possible.14 
 A loading dose of rosuvastatin was found to drastically reduce the amount of all 
cause MACE at 30 days post PCI. MACE, which was defined as cardiac death, MI, and 
target vessel revascularization occurred in 8.1% (5 of 65) of the rosuvastatin group and 
22.2% (14 of 63) in the control group (P <.01). More importantly the incidence of MACE 
at 1 month was completely influenced by postprocedural myocardial infarction (8.1% vs. 
22.2% P <.01, respectively).14 
 The authors do not cite any specific limitations, although one cannot overlook 
their small sample size. The authors do state that a high loading dose of rosuvastatin 
before PCI may reduce postprocedural MI in patients with ACS. They believe it is due to 
the inhibition of inflammatory markers. They do state the need for more studies to clarify 
the involved mechanisms.14 
 
DISCUSSION 
 Many studies5,6,10,16 have touted the beneficial effects of administering a statin 
loading dose to patients before percutaneous coronary intervention (PCI). The 
atorvastatin for reduction of myocardial damage during angioplasty study (ARMYDA 
Trial)10 found that pretreatment with atorvastatin 40mg daily for 7 days significantly 
reduces procedural myocardial injury in elective coronary intervention.10 The ARMYDA-
ACS trial6 found that an 80mg loading dose of atorvastatin 12 hours before PCI in 
patients with non-ST-segment elevation ACS improved outcomes. The NAPLES II trial16 
found that pre-procedural statin therapy reduces the incidence of large non-Q-wave 
myocardial infarction after PCI. 
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This systematic review demonstrates that a 20 to 40mg loading dose of 
rosuvastatin within a time period of 2 to 24 hours before PCI significantly reduces major 
adverse cardiac events at 30 days and up to 12 months in statin naïve patients with ACS 
or stable angina undergoing PCI. While a majority of the cause of MACE at 30 days and 
12 months was due to the reduction in peri-procedural myocardial infarction, it is still 
important to note that rosuvastatin still shows beneficial outcomes up to 12 months post 
PCI. Due to the fact that most of the landmark trials5,6,10 in this setting used atorvastatin, 
many providers are not currently using rosuvastatin. Many providers use atorvastatin 
even though rosuvastatin has outperformed atorvastatin in improving lipid profiles in 
patients with ACS.17 
 One general statement that needs to be made is that even though all of the 
studies12-15 cited a small sample size as a limitation, the treatment effect was large which 
estimates that rosuvastatin is still likely to be beneficial. However, these studies12-15 do 
contain some limitations. One limitation of these studies is that they did not address the 
optimal dose. Another limitation is that they did not discuss the amount of time needed 
between administering rosuvastatin and the procedure. Moreover, the specific “statin 
naïve” patient population all of these studies employed limits the generalizability of the 
results of these studies. Lastly, two of the studies12,13,15 were not blinded. 
CONCLUSION 
 Rosuvastatin has been demonstrated as a safe and effective medication to reduce 
the incidence of peri-procedural myocardial infarction as well as major adverse cardiac 
events in this specific patient population up to 12 months post PCI. The overall combined 
quality of the articles using the GRADE criteria is a score of high moderate. This was due 
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to the studies having a large treatment effect. While many studies have made clear the 
fact that administering a loading dose of a statin before PCI improves outcomes, many 
questions still remain. Is atorvastatin more effective than rosuvastatin in this setting? Is 
statin loading beneficial in patients that present with an ST-segment elevation myocardial 
infarction? Are the beneficial outcomes due to the pleiotropic effects of statins? Many 
more studies need to be done to answer these questions. 
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aNo blinding in the Yun et al study12,15 as well as in the Sardella et al study13 
bSardella et al study13 contained a likely risk for selection bias because it was conducted in just one medical center
Quality Assessment Summary of Findings 
Importance  Downgrade Criteria  Number of Patients Effect 































Yun et al12,15 3 (225) 13 (220) 0.226       22 High 
Moderate Critical Sardella et al
13 7 (80) 24 (80) 0.292 5 
Wang et al14 5 (62) 14 (63) 0.363 8 
Major Adverse Cardiac Events (MACE) at 12 months 












Yun et al12,15 19 (225) 32 (206) 0.544 15 High 
Moderate Critical Sardella et al13 10 (80) 27 (80) 0.37 5 
Myocardial Infarction at 30 days 












Yun et al12,15 2 (225) 5 (220) 0.391 73 
High 
Moderate Critical 
Sardella et al13 7 (80) 21 (80) 0.333 6 
Wang et al14 5 (62) 14 (63) 0.363 8 
Elevated CK-MB levels at 24 hours post-procedure (defined as 3 x Upper Limit of Normal) 












Sardella et al13 7 (80) 21 (80) 0.333 6 High 
Moderate Important Wang et al14 12 (62) 22 (63) 0.554 7 
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